Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us?
Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us?
About this item
Full title
Author / Creator
Publisher
Oxford, UK: Oxford University Press
Journal title
Language
English
Formats
Publication information
Publisher
Oxford, UK: Oxford University Press
Subjects
More information
Scope and Contents
Contents
In 1998, the U.S. Food and Drug Administration granted regulatory approval to the first tumor necrosis factor-α antagonist, infliximab, for the treatment of moderately to severely active Crohn's disease. As of 2013, there were 3 additional tumor necrosis factor-α antagonists commercially available for the treatment of inflammatory bowel disease in...
Alternative Titles
Full title
Tumor Necrosis Factor-Alpha Antagonists Twenty Years Later: What Do Cochrane Reviews Tell Us?
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_miscellaneous_1613941808
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_1613941808
Other Identifiers
ISSN
1078-0998
E-ISSN
1536-4844
DOI
10.1097/MIB.0000000000000218
